TY - JOUR
T1 - Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer
AU - Gumpper-Fedus, Kristyn
AU - Hart, Phil A.
AU - Belury, Martha A.
AU - Crowe, Olivia
AU - Cole, Rachel M.
AU - Grisanti, Valentina Pita
AU - Badi, Niharika
AU - Liva, Sophia
AU - Hinton, Alice
AU - Coss, Christopher
AU - Ramsey, Mitchell L.
AU - Noonan, Anne
AU - Conwell, Darwin L.
AU - Cruz-Monserrate, Zobeida
N1 - Publisher Copyright:
© 2022 by the authorsLicensee MDPI, Basel, Switzerland.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Cachexia occurs in up to 80% of pancreatic ductal adenocarcinoma (PDAC) patients and is characterized by unintentional weight loss and tissue wasting. To understand the metabolic changes that occur in PDAC-associated cachexia, we compared the abundance of plasma fatty acids (FAs), measured by gas chromatography, of subjects with treatment-naïve metastatic PDAC with or without cachexia, defined as a loss of >2% weight and evidence of sarcopenia (n = 43). The abundance of saturated, monounsaturated, and polyunsaturated FAs was not different between subjects with cachexia and those without. Oleic acid was significantly higher in subjects with cachexia (p = 0.0007) and diabetes (p = 0.015). Lauric (r = 0.592, p = 0.0096) and eicosapentaenoic (r = 0.564, p = 0.015) acids were positively correlated with age in cachexia patients. Subjects with diabetes (p = 0.021) or both diabetes and cachexia (p = 0.092) had low palmitic:oleic acid ratios. Linoleic acid was lower in subjects with diabetes (p = 0.018) and correlated with hemoglobin (r = 0.519, p = 0.033) and albumin (r = 0.577, p = 0.015) in subjects with cachexia. Oleic or linoleic acid may be useful treatment targets or biomarkers of cachexia in patients with metastatic PDAC, particularly those with diabetes.
AB - Cachexia occurs in up to 80% of pancreatic ductal adenocarcinoma (PDAC) patients and is characterized by unintentional weight loss and tissue wasting. To understand the metabolic changes that occur in PDAC-associated cachexia, we compared the abundance of plasma fatty acids (FAs), measured by gas chromatography, of subjects with treatment-naïve metastatic PDAC with or without cachexia, defined as a loss of >2% weight and evidence of sarcopenia (n = 43). The abundance of saturated, monounsaturated, and polyunsaturated FAs was not different between subjects with cachexia and those without. Oleic acid was significantly higher in subjects with cachexia (p = 0.0007) and diabetes (p = 0.015). Lauric (r = 0.592, p = 0.0096) and eicosapentaenoic (r = 0.564, p = 0.015) acids were positively correlated with age in cachexia patients. Subjects with diabetes (p = 0.021) or both diabetes and cachexia (p = 0.092) had low palmitic:oleic acid ratios. Linoleic acid was lower in subjects with diabetes (p = 0.018) and correlated with hemoglobin (r = 0.519, p = 0.033) and albumin (r = 0.577, p = 0.015) in subjects with cachexia. Oleic or linoleic acid may be useful treatment targets or biomarkers of cachexia in patients with metastatic PDAC, particularly those with diabetes.
KW - Albumin
KW - Diabetes
KW - Fatty acids
KW - Hemoglobin
KW - Linoleic acid
KW - Oleic acid
KW - Pancreatic cancer
KW - Sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85125995386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125995386&partnerID=8YFLogxK
U2 - 10.3390/cells11050910
DO - 10.3390/cells11050910
M3 - Article
C2 - 35269531
AN - SCOPUS:85125995386
VL - 11
JO - Cells
JF - Cells
IS - 5
M1 - 910
ER -